RxDoctor Payments DataLook up a doctor →

Richard Divalerio, MD

Rheumatology · Saint Louis, MONPI 1841298072

Payments from drug & device makers

$14,146in general payments, 2019–2025

Across 993 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • Pfizer$2K
  • UCB, Inc.$1K
  • Johnson & Johnson$952
  • Novartis$705
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$13,93198%
  • Education$1031%
  • Gifts$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,146 in reported general payments places this provider in the 75th percentile of 134 rheumatology providers in Missouri.

See all rheumatology providers in Missouri

Medicare billing

Part B allowed, 2024
$2,877,375
Medicare patients
429
Services billed
149,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib78$583,732
Humira(Cf) PenAdalimumab33$347,159
Xeljanz XrTofacitinib Citrate48$328,196
Enbrel SureclickEtanercept30$325,208
Humira PenAdalimumab24$173,448
OxycontinOxycodone Hcl24$22,871
Leflunomide363$17,195
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen420$14,322
Xtampza ErOxycodone Myristate13$11,937
EliquisApixaban14$11,598
Hydroxychloroquine Sulfate246$10,234
MethotrexateMethotrexate Sodium462$9,594
Oxycodone Hcl306$6,807
Cevimeline Hcl31$6,803
Fentanyl72$5,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,258$583,73278 claims
PfizerEliquis, Premarin$1,904$16,06530 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$46136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 134 rheumatology providers in Missouri.

Other rheumatology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →